Young Kwang Chae

  • 2142 Citations

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Personalized Cancer Therapy, Precision Medicine, Early Phase Clinical Trials, First-in-Human Study, Novel Combination Cancer Therapy, Targeted therapy, Immunotherapy, Biomarker Study, Novel Drug Development, Novel Drug Delivery System, Adaptive Clinical Trials Design, Cell Signaling Pathway, Immune Checkpoint Pathway

Training Experience

2011Residency, Albert Einstein Medical Center
2014Fellowship, University of Texas/MD Anderson Cancer Center

Education/Academic qualification

MBA, Johns Hopkins University

… → 2007

MPH, Johns Hopkins University

… → 2007

MD, Seoul National University

… → 2002

Research interests

  • Oncology

Fingerprint Dive into the research topics where Young Kwang Chae is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


Research Output

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

Park, W., Mezquita, L., Okabe, N., Chae, Y. K., Kwon, D., Saravia, D., Auclin, E., Planchard, D., Caramella, C., Ferrara, R., Agte, S., Oh, M., Mudad, R., Jahanzeb, M., Suzuki, H., Besse, B. & Lopes, G., Feb 4 2020, In : British Journal of Cancer. 122, 3, p. 340-347 8 p.

Research output: Contribution to journalArticle

  • 1 Scopus citations

    Analysis of cell-free DNA from 32,989 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations

    Rich, T. A., Reckamp, K. L., Chae, Y. K., Doebele, R. C., Iams, W. T., Oh, M., Raymond, V. M., Lanman, R. B., Riess, J. W., Stinchcombe, T. E., Subbiah, V., Trevarthen, D. R., Fairclough, S., Yen, J. & Gautschi, O., Jan 1 2019, In : Clinical Cancer Research. 25, 19, p. 5832-5842 11 p.

    Research output: Contribution to journalArticle

    Open Access
  • 6 Scopus citations

    A phase I dose-escalation study of veliparib combined with carboplatin and etoposide in patients with extensive-stage small cell lung cancer and other solid tumors

    Atrafi, F., Groen, H. J. M., Byers, L. A., Garralda, E., Lolkema, M. P., Sangha, R. S., Viteri, S., Chae, Y. K., Ross Camidge, D., Gabrail, N. Y., Hu, B., Tian, T., Nuthalapati, S., Hoening, E., He, L., Komarnitsky, P. & Calles, A., Jan 15 2019, In : Clinical Cancer Research. 25, 2, p. 496-505 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • 8 Scopus citations

    Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer

    Chae, Y. K., Davis, A. A., Raparia, K., Agte, S., Pan, A., Mohindra, N., Villaflor, V. & Giles, F., Mar 2019, In : Clinical Lung Cancer. 20, 2, p. 88-96.e6

    Research output: Contribution to journalArticle

  • 10 Scopus citations

    Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer

    Chae, Y. K., Viveiros, P., Lopes, G., Sukhadia, B., Sheikh, M. M., Saravia, D., Florou, V., Sokol, E. S., Frampton, G. M., Chalmers, Z. R., Ali, S. M., Ross, J. S., Chang, S., Wang, S., Chiec, L., Rahbari, A., Mohindra, N., Villaflor, V., Shin, S. H., Oh, M. & 5 others, Anker, J., Park, L. C., Wang, V., Chuang, J. & Park, W., Oct 2019, In : Journal of Thoracic Oncology. 14, 10, p. 1807-1817 11 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations